


Abstract

The present invention relates to a crystal form of a sulfoximine compound, a preparation method therefor, and a use thereof. Specifically, disclosed are a crystal form of a compound as shown in a formula (I), a preparation method therefor, and a use thereof. The crystal form has excellent stability, and can be widely applied to the preparation of drugs for preventing and/or treating diseases related to increased FGFR2 activity and expression level. The crystal form is preferably a hydrochloride crystal form I of the compound represented by formula I, and the X-ray powder diffraction pattern of the hydrochloride crystal form I has a 2θ angle selected from the following group: 6.68 ± 0.2 degrees, 13.34 ± 0.2 degrees, and 21.42 ± 0.2 degrees.



No figure